U.S. markets close in 6 hours 10 minutes
  • S&P 500

    4,438.97
    -10.01 (-0.22%)
     
  • Dow 30

    34,718.59
    -46.23 (-0.13%)
     
  • Nasdaq

    14,948.77
    -103.47 (-0.69%)
     
  • Russell 2000

    2,249.74
    -9.30 (-0.41%)
     
  • Crude Oil

    73.38
    +0.08 (+0.11%)
     
  • Gold

    1,741.20
    -8.60 (-0.49%)
     
  • Silver

    22.17
    -0.51 (-2.27%)
     
  • EUR/USD

    1.1715
    -0.0032 (-0.27%)
     
  • 10-Yr Bond

    1.4420
    +0.0320 (+2.27%)
     
  • GBP/USD

    1.3680
    -0.0040 (-0.29%)
     
  • USD/JPY

    110.6690
    +0.3680 (+0.33%)
     
  • BTC-USD

    41,624.29
    -2,491.53 (-5.65%)
     
  • CMC Crypto 200

    1,034.28
    -68.78 (-6.24%)
     
  • FTSE 100

    7,066.08
    -12.27 (-0.17%)
     
  • Nikkei 225

    30,248.81
    +609.41 (+2.06%)
     

Vetr Upgrades Celgene After Drug Trial Stalls

The Vetr crowd on Monday upgraded its rating on Celgene Corporation (NASDAQ: CELG) from 3 stars (Buy) issued 16 days ago, to 5 stars (Strong Buy). Crowd sentiment at the time of the upgrade was unanimously positive, with 100 percent of Vetr user ratings bullish.

Vetr's upgrade comes on the heels of biotech's announcement that it would be discontinuing trials of its crohn's disease drug treatment. Following the news, analysts with Baird and Piper Jaffray downgraded the stock while a slew of others, including analysts with UBS and Barclays, lowered their outlook on the company.

See how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average price target on Celgene is up at $144.39, which is above the average analyst price target of $140.50. Less than 2 percent of Vetr users are holding CELG in their watch-lists.

Latest Ratings for CELG

Oct 2017

Guggenheim

Initiates Coverage On

Buy

Oct 2017

Morgan Stanley

Maintains

Underweight

Oct 2017

PiperJaffray

Assumes

Overweight

Neutral

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

See more from Benzinga

© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.